Date of Publication: 30-01-2026
INTELLIGENCE OVERVIEW
Agency: European Medicines Agency (EMA)
The European Medicines Agency (EMA) has released a draft reflection paper outlining scientific principles for the qualification and control of non-mutagenic impurities in medicinal products .
Industry Impact
This guidance is significant for MAHs, API manufacturers, and pharmaceutical developers as it:
- Clarifies when non-mutagenic impurities require qualification data
- Supports a science- and risk-based approach aligned with product lifecycle management
- Helps avoid over-conservative impurity limits, reducing unnecessary development burden
- Improves regulatory predictability during quality variations and post-approval changes
Overall, the reflection paper strengthens regulatory expectations for impurity justification while enabling more flexible and proportionate quality strategies across the EU.
The European Medicines Agency (EMA) has released a draft reflection paper outlining scientific principles for the qualification and control of non-mutagenic impurities in medicinal products .
Industry Impact
This guidance is significant for MAHs, API manufacturers, and pharmaceutical developers as it:
- Clarifies when non-mutagenic impurities require qualification data
- Supports a science- and risk-based approach aligned with product lifecycle management
- Helps avoid over-conservative impurity limits, reducing unnecessary development burden
- Improves regulatory predictability during quality variations and post-approval changes
Overall, the reflection paper strengthens regulatory expectations for impurity justification while enabling more flexible and proportionate quality strategies across the EU.
https://www.ema.europa.eu/en/qualification-non-mutagenic-impurities-scientific-guideline